News
Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback